Rich Pharmaceuticals, a biopharmaceutical company focused on developing and commercializing innovative therapies in oncology, has selected a site and obtained investigator's interest at Phramongkutklao Hospital in Bangkok, Thailand. Rich has engaged CMIC ASIA-PACIFIC, PTE. LTD. (CMIC) to assist in this project and they have already completed a site selection visit at Phramongkutklao Hospital, and the site has been cleared.
Rich and CMIC are preparing submission packages for the Hospital's Internal Review Board (IRB) and the Thailand FDA. This package is near completion and the Company plans to submit it shortly. "The company has purchased product liability insurance, the package is near completion and we hope to submit in the coming days," said Ben Chang, CEO.
In cooperation with the Hospital, Rich is seeking to conduct a study for the treatment of Acute Myelocytic Leukemia (AML) in refractory patients in a phase I/II trial. Acute Myelocytic Leukemia is a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal white blood cells that build up in the bone marrow and interfere with the production of normal blood cells. AML is the most common acute leukemia affecting adults, and its incidence increases with age. Because the incidence increases with age, it is expected that incidence will rise as population rises.